Disclaimer
Public at large are hereby cautioned about fraudulent activities and false commitments inviting general public at large to deposit/invest funds with trust associated investment activities carried out with malicious intent in the name of CADILA by using deceptive stationary like letterhead, round stamp and thereby wrongly misleading the public at large.
Such activities are carried out by some group of fraudsters with an intention to cheat under wrongful commitment and allurement. Therefore, CADILA advises the general public to not take the bait and avoid giving their confidential details or money to such false/fabricated commitments.
CADILA is not involved in such fraudulent activities and hence is not liable, responsible or answerable in case of any financial deception. CADILA shall not entertain, answer or attend any such fraudulent claims thereunder if any.
Cadila Pharmaceuticals Sweden AB located at Karolinska Institutet Science Park, Solna is a wholly-owned subsidiary of Cadila Pharmaceuticals Limited, India.
Over the last six decades, the company has been developing, manufacturing and selling pharmaceutical products in over eighty-five countries around the world
Drug counterfeiting is a serious offence worldwide and claims many lives every year, while jeopardizing the lives of others. Today, counterfeiters are increasingly employing deceitful tactics to lure people with cheaper, but fatal drugs. Typically, counterfeiting today employs many mechanisms viz. absence of active ingredient, low levels of active ingredient, replacing safe drugs with poor-quality drugs and wrong packaging.
As a responsible corporate house, Cadila Pharmaceuticals Limited has started a drive against infringement or counterfeiting of its products. In this journey we urge you all to join and support us by reporting any type of counterfeiting of any of our products. You can mail us at website@cadilapharma.co.in or call us on +91 - 2718 - 225001 and provide the details of the product mentioned below.
Download in PDF format